The Novel Role of the Mu Opioid Receptor in Lung Cancer Progression
Authors:
- Frances E. LennonFLFrances E. Lennon
- Jessica SieglerJSJessica Siegler
- Tamara MirzapoiazovaTMTamara Mirzapoiazova
- Nurbek MambetsarievNMNurbek Mambetsariev
- Saad SammaniSSSaad Sammani
- Lynnette M. GerholdLGLynnette M. Gerhold
- Patrick J. LaRivierePLPatrick J. LaRiviere
- Chin-Tu ChenCCChin-Tu Chen
- Joe G. N. GarciaJGJoe G. N. Garcia
- Ravi SalgiaRSRavi Salgia
- Jonathan MossJMJonathan Moss
- 1 March 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 112 (3) , 558-567
Abstract
Ible mechanism for these epidemiologic findings on the basis of μ opioid receptor (MOR) regulation of Lewis lung carcinoma (LLC) tumorigenicity in cell and animal models. METHODS: We used human lung tissue and human non–small cell lung cancer (NSCLC) cell lines and evaluated MOR expression using immunoblot and immunohistochemical analysis. LLC cells were treated with the peripheral opioid antagonist methylnaltrexone (MNTX) or MOR shRNA and evaluated for proliferation, invasion, and soft agar colony formation in vitro and primary tumor growth and lung metastasis in C57BL/6 and MOR knockout mice using VisEn fluorescence mediated tomography imaging and immunohistochemical analysis. RESULTS: We provide several lines of evidence that the MOR may be a potential target for lung cancer, a disease with high mortality and few treatment options. We first observed that there is ∼5- to 10-fold increase in MOR expression in lung samples from patients with NSCLC and in several human NSCLC cell lines. The MOR agonists morphine and [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) increased in vitro LLC cell growth. Treatment with MNTX or silencing MOR expression inhibited LLC invasion and anchorage-independent growth by 50%–80%. Injection of MOR silenced LLC lead to a ∼65% reduction in mouse lung metastasis. In addition, MOR knockout mice do not develop significant tumors when injected with LLC in comparison with wild-type controls. Finally, continuous infusion of the peripheral opioid antagonist MNTX attenuates primary LLC tumor growth and reduces lung metastasis. CONCLUSIONS: Taken together, our data suggest a possible direct effect of opiates on lung cancer progression, and provide a plausible explanation for the epidemiologic findings. Our observations further suggest a possible therapeutic role for opioid antagonists....Keywords
This publication has 54 references indexed in Scilit:
- Association between Epidural Analgesia and Cancer Recurrence after Colorectal Cancer SurgeryAnesthesiology, 2010
- Surgery for CancerAnesthesia & Analgesia, 2010
- EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin ActivationJournal of Biological Chemistry, 2010
- Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR InhibitorsJournal of Angiogenesis Research, 2010
- Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammationJournal of Clinical Investigation, 2008
- Anesthetic Technique for Radical Prostatectomy Surgery Affects Cancer RecurrenceAnesthesiology, 2008
- Long-Term Survival After Colon Cancer Surgery: A Variation Associated with Choice of AnesthesiaAnesthesia & Analgesia, 2008
- Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for CancerThe American Journal of Pathology, 2007
- Whole-body imaging with fluorescent proteinsNature Protocols, 2006
- Detection of disseminated tumor cells in peripheral blood of colorectal cancer patientsInternational Journal of Cancer, 1997